A multicenter phase II study of Nivolumab monotherapy in recurrent and/or metastatic gastrointestinal cancer patients with high Tumor Mutation Burden (TMB-H)

ABSTRACT: Interventions: Monotherapy with Nivolumab 360 mg, every 3 weeks intravenous administration Primary outcome(s): Objective response rate (ORR) determined by RECIST v1.1 Study Design: Single arm Non-randomized

DISEASE(S): Colorectal Cancer, Gastric Cancer, Esophageal Cancer, Biliary Tract Cancer, Pancreatic Cancer, And Other Gastrointestinal Cancer

PROVIDER: 2648298 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR